AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31827803 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 3716
Study 31827803 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 3716
Study 31828052 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Aeration Inflation for Infant Lungs (SAIL) intervention
Number of subjects: 460
Study 31828052 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 460
Study 31828307 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sex chromosome dosage
Number of subjects: 301
Study 31828337 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam/avibactam loading dose of 500/137 mg (30 min infusion), followed by maintenance doses of 1500/410 mg (3 h infusions) q6h (Cohort 1)
Number of subjects: 34
Study 31828337 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam/avibactam loading dose of 500/167 mg (30 min infusion), followed by maintenance doses of 1500/500 mg (3 h infusions) q6h (Cohorts 2+3)
Number of subjects: 34
Study 31828337 — intervention group
Group type: EXPERIMENTAL
Intervention: IV metronidazole 500 mg q8h (all patients)
Number of subjects: 34
Study 31828337 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam/avibactam treatment
Number of subjects: 34
Study 31828369 — intervention group
Group type: EXPERIMENTAL
Intervention: ENTRAMI technique for neurolysis
Number of subjects: 15
Study 31828475 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological battery and standardized brain MRI evaluation in patients with Susac syndrome.
Number of subjects: 19
Study 31828475 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain volume and corpus callosum area measurements using 3D-T1 sequences.
Number of subjects: 19
Study 31828611 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine
Number of subjects: 615
Study 31828612 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia
Number of subjects: 592
Study 31828612 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Number of subjects: 592
Study 31828612 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia with Chloroprocaine and Prilocaine
Number of subjects: 592
Study 31828612 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia and Spinal Anesthesia
Number of subjects: 592
Study 31829203 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) at a starting dose of 50 Gy in 5 fractions every other day (biologically effective dose: 100 Gy)
Number of subjects: 39
Study 31829203 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 39
Study 31829732 — intervention group
Group type: EXPERIMENTAL
Intervention: Family encouragement of healthy eating
Number of subjects: 0
Study 31830234 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT for MDS in patients aged 65 years or older
Number of subjects: 1280
Study 31830234 — intervention group
Group type: COMPARATOR
Intervention: HCT for MDS in patients aged 55 to 64 years
Number of subjects: 1280
Study 31830897 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully-covered self-expanding metal stent (FCSEMS)
Number of subjects: 18
Study 31831072 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for daily evolution of disease severity
Number of subjects: 1251
Study 31831151 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI with third-generation prostheses
Number of subjects: 1006
Study 31831151 — intervention group
Group type: COMPARATOR
Intervention: SAVR with Perimount Magna Ease or Trifecta prostheses
Number of subjects: 1006
Study 31831533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian tissue cryopreservation
Number of subjects: 100
Study 31831560 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA-targeted thorium-227 conjugate (PSMA-TTC)
Number of subjects: 0
Study 31831579 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hs-TnI)
Number of subjects: 2085
Study 31832227 — intervention group
Group type: EXPERIMENTAL
Intervention: The StepSmart Challenge (gamification techniques)
Number of subjects: 224
Study 31832225 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF)
Number of subjects: 0
Study 31832240 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO arm (electronic patient-reported outcomes with real-time clinician feedback)
Number of subjects: 682
Study 31832240 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm (short paper tracking list)
Number of subjects: 682
Study 31832240 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO arm
Number of subjects: 682
Study 31832240 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 682
Study 31832240 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 682
Study 31832624 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) - 2.0-fold individual total plasma volume on day 1, 2.5-fold on days 2-5, 5 treatments over 5 consecutive days.
Number of subjects: 61
Study 31832624 — intervention group
Group type: COMPARATOR
Intervention: Plasma Exchange (PE) - 2 liters of plasma removed each day, substituted by 5% human albumin solution, 5 treatments over 5 consecutive days.
Number of subjects: 61
Study 31832728 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE (group A, n=6)
Number of subjects: 33
Study 31832728 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE (group B, n=7)
Number of subjects: 33
Study 31832728 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE (group C, n=6)
Number of subjects: 33
Study 31832728 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE (group D, n=14)
Number of subjects: 33
Study 31832728 — intervention group
Group type: EXPERIMENTAL
Intervention: EBTATE groups (B-D combined)
Number of subjects: 33
Study 31832728 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 33
Study 31833010 — intervention group
Group type: EXPERIMENTAL
Intervention: V-Go insulin delivery device
Number of subjects: 188
Study 31833414 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous stent placement using the Vici Venous Stent System (self-expanding nitinol stent)
Number of subjects: 170
Study 31833414 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous stent placement using the Vici Venous Stent System
Number of subjects: 170
Study 31833416 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional diagnostic procedure with reference invasive tests including coronary flow reserve, microvascular resistance, and vasomotor responses to intracoronary acetylcholine.
Number of subjects: 391
Study 31833416 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducible ischemia on treadmill testing.
Number of subjects: 391
Study 31833416 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of identifiable disorders of coronary vasomotion in INOCA patients.
Number of subjects: 391
Study 31833416 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life comparison between INOCA patients and those with obstructive coronary artery disease.
Number of subjects: 391
Study 31833973 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted axillary dissection (TAD) in biopsy-proven node-positive patients who convert to clinical node negativity after NACT.
Number of subjects: 0
Study 31833973 — intervention group
Group type: COMPARATOR
Intervention: Standard axillary lymph node dissection in sentinel lymph node-positive patients.
Number of subjects: 0
Study 31834121 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary aldosteronism identified in 73 patients (42% prevalence)
Number of subjects: 411
Study 31834121 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically curable forms of primary aldosteronism
Number of subjects: 411
Study 31834219 — intervention group
Group type: EXPERIMENTAL
Intervention: 360° turn test
Number of subjects: 104
Study 31834219 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined models including 360° turn test and tandem walk test
Number of subjects: 104
Study 31834219 — intervention group
Group type: EXPERIMENTAL
Intervention: One-leg stance test
Number of subjects: 104
Study 31834219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem walk test
Number of subjects: 104
Study 31834219 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive postural control test
Number of subjects: 104
Study 31834365 — intervention group
Group type: EXPERIMENTAL
Intervention: tau368/t-tau ratio
Number of subjects: 95
Study 31834365 — intervention group
Group type: EXPERIMENTAL
Intervention: tau368 presence in tangles
Number of subjects: 95
Study 31834365 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF tau368/t-tau ratio
Number of subjects: 95
Study 31834916 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]THK-5351 PET in MCI
Number of subjects: 65
Study 31834916 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]THK-5351 PET in AD
Number of subjects: 65
Study 31834916 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]THK-5351 PET in β-amyloid PET-positive group
Number of subjects: 65
Study 31834916 — intervention group
Group type: COMPARATOR
Intervention: [18F]THK-5351 PET in normal controls
Number of subjects: 65
Study 31835236 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (G) 1000 mg/m² combined with Pazopanib (P) for a median of 3.8 months
Number of subjects: 106
Study 31835236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (P) alone for a median of 4.2 months
Number of subjects: 106
Study 31835495 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1125976 (allosteric AKT inhibitor)
Number of subjects: 28
Study 31836026 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Individual Dietary Diversity (WIDD) score
Number of subjects: 432
Study 31836026 — intervention group
Group type: EXPERIMENTAL
Intervention: Not consuming animal source foods
Number of subjects: 432
Study 31836026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing anemia
Number of subjects: 432
Study 31836026 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dietary diversity (DD) during pregnancy
Number of subjects: 432
Study 31836026 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of anemia
Number of subjects: 432
Study 31836507 — intervention group
Group type: EXPERIMENTAL
Intervention: Social dysfunction indicator derived from Sheehan Disability Scale (SDS) for GSRD sample
Number of subjects: 765
Study 31836507 — intervention group
Group type: EXPERIMENTAL
Intervention: Social dysfunction indicator derived from Work and Social Adjustment Scale (WSAS) for STAR*D sample
Number of subjects: 765
Study 31836507 — intervention group
Group type: EXPERIMENTAL
Intervention: Social dysfunction indicator derived from Life-Range of Impaired Functioning Tool (LRIFT) for STEP-BD sample
Number of subjects: 765
Study 31836507 — intervention group
Group type: EXPERIMENTAL
Intervention: Social dysfunction indicator derived from Quality of Life Scale (QOLS) for CATIE sample
Number of subjects: 765
Study 31836590 — intervention group
Group type: EXPERIMENTAL
Intervention: 1q21.1 deletion and a rare functional polymorphism
Number of subjects: 2
Study 31836661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasting sweet, salty, sour, and tasteless liquids using ultra-high resolution functional magnetic resonance imaging (MRI) at 7-tesla.
Number of subjects: 0
Study 31836661 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate searchlight analyses decoding distinct tastes.
Number of subjects: 0
Study 31836680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 31836680 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 31836928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (2000/500 mg by 2-h intravenous infusion every 8 h, adjusted for renal function)
Number of subjects: 0
Study 31836928 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 0
Study 31836927 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg twice-daily oral administration of cimetidine
Number of subjects: 14
Study 31836927 — intervention group
Group type: COMPARATOR
Intervention: lucerastat administered alone
Number of subjects: 14
Study 31837149 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute episodes (AEs) of RARS
Number of subjects: 202
Study 31837149 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy findings during AEs
Number of subjects: 202
Study 31837149 — intervention group
Group type: COMPARATOR
Intervention: Between AEs
Number of subjects: 202
Study 31837149 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy findings without AEs
Number of subjects: 202
Study 31837266 — intervention group
Group type: EXPERIMENTAL
Intervention: CPD for sleep
Number of subjects: 223
Study 31837266 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 223
Study 31837266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis of CPD for sleep vs. event schedules
Number of subjects: 223
Study 31837624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy (CBGT)
Number of subjects: 59
Study 31838007 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib (600 mg orally once per day)
Number of subjects: 54
Study 31838015 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib (600 mg orally once per day)
Number of subjects: 134
Study 31838114 — intervention group
Group type: EXPERIMENTAL
Intervention: Arithmetic mean method for calculating implantation depth (ID)
Number of subjects: 258
Study 31838114 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncoronary cusp distance method for calculating ID
Number of subjects: 258
Study 31838114 — intervention group
Group type: EXPERIMENTAL
Intervention: Deepest edge method for calculating ID
Number of subjects: 258
Study 31838114 — intervention group
Group type: EXPERIMENTAL
Intervention: Deepest edge method for ID vs. no optimal ID
Number of subjects: 258
Study 31838114 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean pressure gradient reduction after TAVR (OID vs. no OID)
Number of subjects: 258
Study 31838257 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31838512 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D patients
Number of subjects: 28
Study 31838512 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (CON)
Number of subjects: 28
Study 31838576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 13
Study 31838872 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 118
Study 31838872 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 118
Study 31838939 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine, oxaliplatin, and capecitabine
Number of subjects: 0
Study 31838969 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) analysis using the HeartTrends DyDx algorithm during 1-hour Holter testing
Number of subjects: 1043
Study 31838969 — intervention group
Group type: COMPARATOR
Intervention: Exercise stress echocardiography
Number of subjects: 1043
Study 31838969 — intervention group
Group type: COMPARATOR
Intervention: Exercise myocardial perfusion imaging
Number of subjects: 1043
Study 31839594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (< 10 ng/mL)
Number of subjects: 645
Study 31839594 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D low level (10-29.9 ng/mL)
Number of subjects: 645
Study 31839594 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D normal level (≥ 30 ng/mL)
Number of subjects: 645
Study 31839962 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic resection of large colorectal lesions (LCLs)
Number of subjects: 1504
Study 31839962 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding prophylaxis
Number of subjects: 1504
Study 31839962 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple polypectomy
Number of subjects: 1504
Study 31839962 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient setting
Number of subjects: 1504
Study 31839962 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic setting
Number of subjects: 1504
Study 31839962 — intervention group
Group type: EXPERIMENTAL
Intervention: Size of lesion
Number of subjects: 1504
Study 31839962 — intervention group
Group type: EXPERIMENTAL
Intervention: Indication for colonoscopy (screening vs diagnostic)
Number of subjects: 1504
Study 31839962 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy
Number of subjects: 1504
Study 31839988 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydroxyapatite toothpaste
Number of subjects: 2
Study 31839988 — intervention group
Group type: COMPARATOR
Intervention: 500 ppm fluoride toothpaste
Number of subjects: 2
Study 31839997 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic influenza virus vaccine (AS03-adjuvanted)
Number of subjects: 0
Study 31839997 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic influenza virus vaccine (A/H9N2)
Number of subjects: 0
Study 31839997 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-vaccination serum from vaccinees
Number of subjects: 0
Study 31839997 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric HA stalk-based universal influenza virus vaccine
Number of subjects: 0
Study 31840425 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (duration: 1 year)
Number of subjects: 105
Study 31840755 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-supervised nonsurgical weight management program
Number of subjects: 479
Study 31841594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg daily
Number of subjects: 34
Study 31841598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraprocessed food consumption (UPF)
Number of subjects: 104707
Study 31842870 — intervention group
Group type: EXPERIMENTAL
Intervention: Active and adaptive case finding (AACF)
Number of subjects: 0
Study 31842870 — intervention group
Group type: COMPARATOR
Intervention: Census case finding
Number of subjects: 0
Study 31842931 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood gas analysis (BGA) from central venous blood
Number of subjects: 15
Study 31842931 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood gas analysis (BGA) from peripheral venous blood
Number of subjects: 15
Study 31842931 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood gas analysis (BGA) from femoral artery
Number of subjects: 15
Study 31842931 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical laboratory analysis (CL) from central venous blood
Number of subjects: 15
Study 31842931 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decisions based on potassium measurement
Number of subjects: 15
Study 31842963 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Navigation (FN) delivery strategies
Number of subjects: 304
Study 31843002 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation (TPTNS)
Number of subjects: 500
Study 31843002 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 500
Study 31843002 — intervention group
Group type: EXPERIMENTAL
Intervention: TPTNS
Number of subjects: 500
Study 31843273 — intervention group
Group type: COMPARATOR
Intervention: EZH2 mRNA expression in tumor specimens
Number of subjects: 87
Study 31843273 — intervention group
Group type: COMPARATOR
Intervention: EZH2 protein expression in tumor specimens
Number of subjects: 87
Study 31843273 — intervention group
Group type: COMPARATOR
Intervention: EZH2 protein expression in primary tumors
Number of subjects: 87
Study 31843273 — intervention group
Group type: COMPARATOR
Intervention: EZH2 mRNA expression in primary tumors
Number of subjects: 87
Study 31843273 — intervention group
Group type: COMPARATOR
Intervention: High EZH2 expression levels
Number of subjects: 87
Study 31843588 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset of venous thromboembolism (VTE) during follow-up
Number of subjects: 731
Study 31843588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of VTE at 3 months
Number of subjects: 731
Study 31843588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of VTE at 12 months
Number of subjects: 731
Study 31843588 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor location (isthmus vs head)
Number of subjects: 731
Study 31843588 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage (locally advanced vs resectable or borderline)
Number of subjects: 731
Study 31843588 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage (metastatic vs resectable or borderline)
Number of subjects: 731
Study 31843588 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS) in patients who developed VTE
Number of subjects: 731
Study 31843588 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) in patients who developed VTE
Number of subjects: 731
Study 31843846 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Reconstruction (BR)
Number of subjects: 10000
Study 31843846 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncoplastic Breast-Conserving Surgery (OBCS)
Number of subjects: 10000
Study 31843865 — intervention group
Group type: EXPERIMENTAL
Intervention: HTX-011
Number of subjects: 0
Study 31843865 — intervention group
Group type: COMPARATOR
Intervention: Liposomal bupivacaine (preclinical only)
Number of subjects: 0
Study 31843865 — intervention group
Group type: COMPARATOR
Intervention: Oral meloxicam (preclinical only)
Number of subjects: 0
Study 31843865 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 31843948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittently scanned continuous glucose monitoring (isCGM)
Number of subjects: 1913
Study 31843947 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC 0/1-h algorithm
Number of subjects: 3681
Study 31843947 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC 0/3-h algorithm
Number of subjects: 3681
Study 31843947 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative cutoffs for both algorithms
Number of subjects: 3681
Study 31844555 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-conferencing based interventions
Number of subjects: 0